source
- Bristol Myers Squibb partners with Institute for Healthcare Improvement to increase cancer trial participationBristol Myers Squibb has entered a three-year collaboration with the Institute for Healthcare Improvement called the Cancer Collective Action Collaborative. The program will bring together 24 team…
- BioNTech's HER2-directed ADC shows modest benefit and higher lung toxicity in phase 3 trialBioNTech reported results of its phase 3 DYNASTY-Breast02 trial evaluating trastuzumab pamirtecan (t-pam), an HER2-directed antibody-drug conjugate, in patients with HR-positive, HER2-low metastati…